Articles: chronic.
-
Patient satisfaction is tied to outcome, but there is scant literature on the relationship of patient perceived outcome and attributes of the pain clinic visit, including the patient interaction with the pain management specialist. The primary purpose of this study is to identify attributes of the patient-provider interaction most strongly associated with patient perceived outcome of their clinic visit. The secondary aim is to correlate patient perceived outcome with patient self-rated overall health. ⋯ Our results suggest that pain physicians may positively impact patient perceived outcomes of clinic visits by explaining the patient's condition and treatment, providing instructions, and taking the time to understand the patient and their values.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Treatment guidelines for chronic obstructive pulmonary disease (COPD) recommend combination therapy of 2 or more long-acting bronchodilators with different mechanisms of action. Here we report the long-term safety of a fixed-dose combination of aclidinium bromide, a long-acting muscarinic antagonist indicated for maintenance treatment of COPD-associated bronchospasm, with formoterol fumarate, a long-acting β2-agonist, in patients with COPD. ⋯ Barry Make: Consultant fee, speaker bureau, advisory committee, etc.: Barry Make received payment for service on the advisory boards of Forest Pharmaceuticals, AstraZeneca, Novartis, Merck, Boehringer Ingelheim, Pfizer, Ikaria, and GlaxoSmithKline, consulting fees from Astellas Pharma, and Talecris Biotherapeutics, lecture fees from GlaxoSmithKline, Boehringer Ingelheim, Pfizer, and Forest Pharmaceuticals, payment for video presentation preparation from Boehringer Ingelheim and Pfizer, payment for document reviews from Spiration., Grant monies (from industry related sources): Barry Make received grant support from AstraZeneca, GlaxoSmithKline, Pfizer, Nabi Biopharmaceuticals, Boehringer Ingelheim, Forest, and Sunovion, Grant monies (from sources other than industry): Barry Make received grant support from the National Heart Lung, and Blood Institute, James Donohue: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Donohue has received consultant/speaker/advisory fees from Novartis, GlaxoSmithKline, Boehringer-Ingelheim, Forest and Pfizer Xiaoyun Zhong: Employee: X. Zhong is an employee of Forest Research Institute, Inc. Anne Leselbaum: Employee: Anne Leselbaum is an employee of Almirall S.A. Cynthia Caracta: Employee: Cynthia Caracta is an employee of Forest Research Institute, Inc., Shareholder: Cynthia Caracta is is a stockowner and has received stock options from Forest Laboratories, Inc.Aclidinium bromide (Tudorzo/Pressair, Eklira/Genuair, Breo/Ellipta) is approved for the maintenance treatment of COPD-associated bronchspasm. The fixed-dose combination of aclidinium bromide/formoterol fumarate is being developed, but not yet approved, for its commercial use for the treatment of COPD.
-
COPD Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Acute exacerbation is a common cause of hospital admission in patients with chronic obstructive pulmonary disease (COPD). COPD also involves non-pulmonary manifestations including exercise intolerance and skeletal muscle dysfunction. These manifestations added to the hospitalization stay have been associated to a loss of muscle mass partially recovered 3 months after discharge. The aims of this study were to examine the effects of a physical therapy (PT) program in hospitalized patients due to an acute exacerbation of COPD (AE-COPD). ⋯ The following authors have nothing to disclose: Irene Torres-Sánchez, Marie Carmen Valenza, Gerald Valenza-Demet, Irene Cabrera-Martos, María José Flores-Barba, Sonia Rodríguez-MoralesNo Product/Research Disclosure Information.
-
Symptoms of Respiratory Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Studies of military personnel deployed to Operations Iraqi Freedom and Enduring Freedom have suggested an increase in chronic lung disease due to environmental exposures. Findings are based primarily on increased respiratory symptoms and retrospective data. Our previous study (STAMPEDE I) did not identify any acute interstitial or inflammatory process. The study objective was to complete a comprehensive evaluation of active duty military with deployment-related pulmonary symptoms and identify etiology of symptoms. ⋯ Michael Morris: Consultant fee, speaker bureau, advisory committee, etc.: Speaker Bureau for Spiriva with Pfizer/Boehringer/Ingelheim The following authors have nothing to disclose: Andrew Skabelund, Georgette Haislip, Pedro LuceroNo Product/Research Disclosure Information.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Evaluate the impact of lung disease(COPD) chronic obstructive in the quality of life of these patients in the province of Albacete. ⋯ The following authors have nothing to disclose: José Luis Castro Navarro, Miguel Angel Palomino Medina, Pedro J. Tárraga López, Juan Solera Albero, Angel Celada Rodríguez, Enrique Arjona LabordaNo Product/Research Disclosure Information.